Equities research analysts expect that KemPharm, Inc. (NASDAQ:KMPH) will post ($0.70) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have issued estimates for KemPharm’s earnings. The lowest EPS estimate is ($0.71) and the highest is ($0.68). KemPharm reported earnings per share of ($0.68) in the same quarter last year, which would suggest a negative year over year growth rate of 2.9%. The company is scheduled to announce its next earnings report on Thursday, March 8th.
On average, analysts expect that KemPharm will report full-year earnings of ($2.67) per share for the current year, with EPS estimates ranging from ($2.70) to ($2.64). For the next financial year, analysts expect that the business will post earnings of ($2.60) per share, with EPS estimates ranging from ($2.65) to ($2.54). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow KemPharm.
KemPharm (NASDAQ:KMPH) last posted its quarterly earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.01.
Several brokerages have recently weighed in on KMPH. Zacks Investment Research lowered shares of KemPharm from a “buy” rating to a “hold” rating in a research report on Wednesday. ValuEngine upgraded shares of KemPharm from a “strong sell” rating to a “sell” rating in a research report on Monday, October 23rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $8.15.
In other news, EVP Daniel L. Cohen purchased 7,500 shares of the business’s stock in a transaction that occurred on Monday, November 27th. The stock was purchased at an average cost of $3.79 per share, with a total value of $28,425.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 22.80% of the company’s stock.
An institutional investor recently raised its position in KemPharm stock. Alyeska Investment Group L.P. boosted its position in shares of KemPharm, Inc. (NASDAQ:KMPH) by 1.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 992,338 shares of the specialty pharmaceutical company’s stock after purchasing an additional 17,721 shares during the period. Alyeska Investment Group L.P. owned about 6.77% of KemPharm worth $3,672,000 at the end of the most recent quarter. 36.04% of the stock is currently owned by hedge funds and other institutional investors.
Shares of KemPharm (NASDAQ:KMPH) remained flat at $$5.00 during trading on Friday. 76,446 shares of the stock traded hands, compared to its average volume of 52,272. The company has a debt-to-equity ratio of -1.92, a quick ratio of 7.56 and a current ratio of 7.56. KemPharm has a fifty-two week low of $2.45 and a fifty-two week high of $5.40. The firm has a market capitalization of $73.28, a price-to-earnings ratio of -1.89 and a beta of -1.09.
TRADEMARK VIOLATION WARNING: This report was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.watchlistnews.com/1807332-2/1807332.html.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.